Crystec, Biosidus Collaborate on Enhanced Delivery and Performance of Biotherapeutics

Published on: 

Crystec and Biosidus have joined forces to enhance the delivery and performance of biotherapeutics.

UK-based crystal and particle-engineering company, Crystec, and Argentinian company, Biosidus, have joined forces to enhance the delivery and performance of biotherapeutics, it was announced in an Oct. 19, 2021 press release.

Using Crystec’s proprietary modified supercritical antisolvent (mSAS) supercritical fluid particle engineering platform on selected Biosidus products, the companies hope to be able to generate a range of innovative, differentiated medicines. Initially, the partnership will focus on accelerating the development of a dry powder preparation of teriparatide for the treatment of osteoporosis.

Currently, teriparatide typically needs to be administered by daily injections over a two-year period. Crystec and Biosidus are hoping to be able to eliminate the need for daily injections by developing the dry preparation of the drug that can be used in formulations for administration via alternative routes, such as the nose.

“We are passionate about making our vital therapies accessible and convenient for those who require them. Our ultimate ambition is to eliminate the need for daily injections meaning that men, women, and children who suffer from long-term and chronic illnesses are not subjected to additional discomfort in the course of their treatment,” said Marcelo Criscuolo, scientific director at Biosidus, in the press release. “Working with Crystec’s innovative mSAS technology opens up the possibility of maximizing the therapeutic potential of these drugs through retaining improved biological activity levels and enabling ‘needle free’ delivery options for our patients.”


“We are delighted to work with Biosidus in this important area of drug delivery,” added Paul Thorning, CEO, Crystec, in the press release. “Our collaboration provides significant potential to demonstrate the power of the mSAS platform in simplifying biopharmaceutical processing, whilst facilitating the accelerated development of inhaled and nasal products that could be truly transformative for patients.”

Source: Crystec